BioLife Solutions Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions or view top-rated stocks.

Wall Street analysts have given BioLife Solutions a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioLife Solutions wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BioLife Solutions.

BioLife Solutions, Inc. (NASDAQ:BLFS) announced its quarterly earnings data on Wednesday, May, 12th. The medical equipment provider reported ($0.03) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.02. The medical equipment provider had revenue of $16.85 million for the quarter, compared to analysts' expectations of $15.60 million. BioLife Solutions had a negative trailing twelve-month return on equity of 0.35% and a negative net margin of 39.34%.
View BioLife Solutions' earnings history.

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLFS shares have increased by 223.3% and is now trading at $39.60.
View which stocks have been most impacted by COVID-19.

BioLife Solutions updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $106 million-115 million, compared to the consensus revenue estimate of $105.65 million.

9 Wall Street analysts have issued 1 year target prices for BioLife Solutions' stock. Their forecasts range from $33.00 to $61.00. On average, they anticipate BioLife Solutions' stock price to reach $50.38 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts' price targets for BioLife Solutions or view top-rated stocks among Wall Street analysts.

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to BioLife Solutions include LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Outset Medical (OM), Natus Medical (NTUS), ViewRay (VRAY), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Semler Scientific (SMLR), Stereotaxis (STXS), Zynex (ZYXI), Edap Tms (EDAP), Second Sight Medical Products (EYES) and Movano (MOVE).
View all of BLFS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

BioLife Solutions' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.89%), Wasatch Advisors Inc. (3.36%), Geneva Capital Management LLC (3.09%), Ameriprise Financial Inc. (2.72%), Russell Investments Group Ltd. (1.93%) and TimesSquare Capital Management LLC (1.45%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger.
View institutional ownership trends for BioLife Solutions.

BLFS stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Wasatch Advisors Inc., Russell Investments Group Ltd., Tower House Partners LLP, Sentinel Pension Advisors Inc., Jennison Associates LLC, D. E. Shaw & Co. Inc., and Calamos Advisors LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Andrew G Hinson, Greef Roderick De, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard, and Walter Villiger.
View insider buying and selling activity for BioLife Solutions or view top insider-selling stocks.

BLFS stock was bought by a variety of institutional investors in the last quarter, including Geneva Capital Management LLC, Palisade Capital Management LLC NJ, Millennium Management LLC, RMB Capital Management LLC, Premier Fund Managers Ltd, Victory Capital Management Inc., JPMorgan Chase & Co., and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.
View insider buying and selling activity for BioLife Solutions or or view top insider-buying stocks.

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLFS stock can currently be purchased for approximately $39.60.

BioLife Solutions has a market capitalization of $1.60 billion and generates $48.09 million in revenue each year. The medical equipment provider earns $2.67 million in net income (profit) each year or $0.01 on an earnings per share basis.

BioLife Solutions employs 193 workers across the globe.

The official website for BioLife Solutions is www.biolifesolutions.com.

BioLife Solutions is headquartered at 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]